TLR4/P2X7-NLRP3 signaling pathway

Overview

The TLR4/P2X7-NLRP3 signaling pathway is an innate immune signaling axis that links extracellular danger sensing to inflammasome activation and downstream inflammatory cytokine release. In this pathway, TLR4 (toll-like receptor 4) functions as a pattern-recognition receptor that detects microbial products and endogenous danger signals, while P2X7 is an ATP-gated purinergic receptor that can amplify inflammatory responses under conditions of cellular stress or tissue injury. Activation of these upstream sensors converges on the NLRP3 inflammasome, a multiprotein complex that promotes caspase-1 activation and maturation of Interleukin 1 beta and IL18, thereby contributing to pyroptosis and inflammatory tissue damage.

Biologically, this signaling cascade is important in sterile inflammation, neuroinflammation, pain, autoimmune disease, and antitumor immunity. It is also a frequent pharmacologic target because modulation of TLR4, P2X7, or NLRP3 can alter the balance between protective immune activation and pathological inflammation. In recent studies, the pathway has been examined in contexts ranging from paclitaxel-induced peripheral neuropathic pain to cerebral ischemia-reperfusion injury and rheumatoid arthritis, and it has also been considered in relation to immune adjuvants and antitumor strategies.

Focus of Latest Publications

Recent publications have examined the TLR4/P2X7-NLRP3 signaling pathway primarily as a mechanistic target in inflammatory and pain-related disease models, with most studies assessing whether therapeutic interventions suppress pathway activation and downstream pyroptotic or cytokine responses. In a murine model of paclitaxel-induced peripheral neuropathic pain, electroacupuncture was tested at different intensities and found to alleviate mechanical allodynia and thermal hyperalgesia, with the strongest effect reported at 1.0 mA. The study linked this analgesic action to reduced activation of TLR4, P2X7, NLRP3, NF-κB, IL-1β, and IL-18 in dorsal root ganglia and spinal cord, alongside decreased expression of pain-related neurotransmitters such as substance P, CGRP, and p75 in plantar tissues.

Other recent work has implicated the broader TLR4/NF-κB/NLRP3 axis in neuroinflammation after cerebral ischemia-reperfusion injury. In rat and BV-2 cell models, amygdalin improved neurological outcomes, reduced inflammatory and oxidative stress responses, and suppressed microglial M1 polarization while promoting M2-related phenotypes. Multi-omics analysis and inhibitor experiments identified TLR4, Myd88, Nlrp3, and Caspase-1 as key candidate molecules, and the authors concluded that the protective effects of amygdalin depended on regulation of the TLR4/NF-κB/NLRP3 signaling axis rather than additive synergy with either TLR4 or NLRP3 inhibition.

The pathway has also appeared in studies of immune activation and inflammasome biology beyond pain and stroke. In one report, nano-granulated zoledronate was developed as an immune-metabolic adjuvant that enhanced vaccine-induced and antitumor immunity, and when combined with the TLR4 agonist monophosphoryl lipid A it produced robust humoral and antitumor cellular responses. Although this study focused on mevalonate-pathway metabolism and pyrin inflammasome activation rather than TLR4/P2X7-NLRP3 directly, it reinforces the use of TLR4-centered innate immune stimulation as a strategy for amplifying inflammatory signaling in therapeutic settings.

Across these publications, the TLR4/P2X7-NLRP3 pathway is presented as a modifiable inflammatory node whose inhibition is associated with reduced neuroinflammation, pyroptosis, and pain signaling, while TLR4-directed immune activation is leveraged in vaccine and antitumor approaches. The studies collectively support the pathway’s relevance in chemotherapy-induced neuropathy and ischemic injury, and they highlight electroacupuncture and amygdalin as interventions associated with suppression of TLR4-linked inflammasome signaling, IL-1β/IL-18 production, and related inflammatory mediators.

Key Publications

• May The analgesic effect of electroacupuncture in alleviating paclitaxel-induced peripheral neuropathic pain and its possible mechanism relates to TLR4/P2X7-NLRP3 signaling pathway. (Purinergic signalling, 2026, PMID 42118387): "Paclitaxel administration upregulated substance P, CGRP, and p75 in plantar tissues and activated the TLR4/P2X7-NLRP3 signaling pathway in DRG and spinal cord, as evidenced by increased expression of TLR4, P2X7, NLRP3, NF-κB, IL-1β, and IL-18."
• May Probing Immune Signatures of Conjugated Pattern Recognition Receptor Ligands Identifies Chimeras with Potent Adjuvant and Antitumor Activities. (Journal of medicinal chemistry, 2026, PMID 42087448): "Among these, chimeric TLR4/TLR7 and TLR7/RIG-I ligands elicited broad innate immune activation in vitro and enhanced antigen-specific immune responses in murine vaccination models."
• May The "Tianyu" Formulation Alleviates Rheumatoid Arthritis by Modulating the NLRP3/Caspase-1/GSDMD-Mediated Pyroptosis Pathway. (FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026, PMID 42033182): "...downregulated the expression of key proteins involved in pyroptosis mediated by the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome."
• May Nano-granulated zoledronate sensitizes innate immune metabolism to enhance vaccine-induced and antitumor immunity. (Cell reports. Medicine, 2026, PMID 42025165): "By integrating Nano-ZD with the TLR4 agonist monophosphoryl lipid A (MPLA), MPLA-loaded Nano-ZD (Nano-ZDM) elicits robust humoral and antitumor cellular immunity."
• May Amygdalin attenuates post-ischemic neuroinflammation by targeting TLR4/NF-κB signaling and NLRP3 inflammasome in cerebral ischemia-reperfusion injury. (European journal of pharmacology, 2026, PMID 42013993): "...and identified Tlr4, Myd88, Nlrp3, and Caspase-1 as key candidate molecules;"
• Jul Tumor Homing Nanoparticle Immunotherapy for Acute Clearance and Mitigation of T-cell Exhaustion in Humanized High-Risk Neuroblastoma. (Molecular cancer therapeutics, 2026, PMID 41885070): "Specifically, our immunomodulatory NPs (immuno-NPs) co-deliver agonists of the stimulator of interferon (IFN) genes and Toll-like receptor 4 pathways."
• May NADPH exerts neuroprotection in ischemic stroke by reinforcing blood-brain barrier integrity and stimulating angiogenesis. (Neuropharmacology, 2026, PMID 41638470): "Through network pharmacology analysis and molecular docking, five key molecular targets of NADPH in IS were identified: HIF-1α, SRC, NLRP3, CASP3, and AKT1."